However, at the same time, these cross-reactive antibodies should also have neutralizing property; otherwise, they will have a harmful effect. A recent study explored the cross-reactive and neutralization property of these antibodies simultaneously (Lv et al., 2020). This study used plasma from 15 SARS-CoV-2 and 7 SARS-CoV patients and found a high degree of cross-reactivity between the antibody response from these samples, but a very low antibody neutralizing property. These results were further confirmed in animal models of SARS-CoV-2 and SARS-CoV. While S309 antibody showed better neutralization property against SARS-CoV-2, the neutralization properties for CR3022 are not yet known (Pinto et al., 2020; Wang et al., 2020a). Thus, although a high degree of cross-reactivity of the antibody response from SARS-CoV-2 can be found with other related CoVs, the neutralizing property of these antibodies may be epitope specific. The weak neutralizing property of such cross-reactive antibodies should thoroughly be tested before usage as a therapeutic intervention, to prevent the complications which may arise due to antibody-dependent enhancement (ADE). These factors also become essential while considering convalescent plasma therapy.